HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preclinical evaluation of dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and budotitane. Two representatives of the new class of antitumor-active bis-beta-diketonato metal complexes.

Abstract
The antitumor-active bis-beta-diketonato metal complexes dichlorobis(1-phenylbutane-1,3-dionato)titanium (IV) and diethoxybis(1-phenylbutane-1,3-dionato)titanium (IV) (prop. INN: budotitane) are active against several transplantable tumors. Activity was demonstrated by treating the intramusculary, subcutaneously and intraperitoneally transplanted sarcoma 180 tumor and against the Walker 256 Carcinosarcoma as well. In these models an increase in survival time up to T/C-values of 200 to 300% (T/C = (median survival time of treated animals to that of controls) X 100) and reduction of tumor weight to 30 or 0%, compared with the untreated control animals, was demonstrated. The therapy of the leukemias P 388 and L 1210 turned out to be statistically significant but only marginal in terms of increase in survival time (T/C approximately 130%). The toxicological experiments demonstrate single doses up to 40 mg/kg, given intravenously in female SD-rats, as to be well tolerable. The dose 80 mg/kg caused lethality in the range between 14 and 50% in 3 independent experiments. The spontaneously dying animals showed haemorrhagic pleural effusions and haemorrhagic oedematous areas of the lung. Histopathologically hyperemia and multiple focal necroses of the liver were found. The described lung toxicity was found only in high, single and lethal doses. Chronic doses of 10 to 20 mg/kg caused only mild liver toxicity. The laboratory parameters were increased in the values of the enzymes GOT, GPT and LDH. No evidence of myelosuppression was found in the peripheral blood.(ABSTRACT TRUNCATED AT 250 WORDS)
AuthorsB K Keppler, D Schmähl
JournalArzneimittel-Forschung (Arzneimittelforschung) Vol. 36 Issue 12 Pg. 1822-8 (Dec 1986) ISSN: 0004-4172 [Print] Germany
PMID3566844 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Organometallic Compounds
  • dichlorobis(1-phenyl-1,3-butanedionato)titanium (IV)
  • Titanium
  • diethoxy-(1-phenyl-1,3-butanedionato)titanium (IV)
  • Cisplatin
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Body Weight (drug effects)
  • Carcinoma 256, Walker (drug therapy)
  • Chemistry, Pharmaceutical
  • Cisplatin (pharmacology)
  • Columbidae
  • Drug Evaluation, Preclinical
  • Leukemia L1210 (drug therapy)
  • Leukemia P388 (drug therapy)
  • Male
  • Mice
  • Mice, Inbred Strains
  • Neoplasm Transplantation
  • Organometallic Compounds (pharmacology, toxicity)
  • Rats
  • Sarcoma 180 (drug therapy)
  • Titanium (pharmacology, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: